Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on RGLS stock, giving a Buy rating on March 14.
Joseph Schwartz has given his Buy rating due to a combination of factors including the promising developments in Regulus’s lead asset, Farabursen (RGLS8429), which targets microRNA 17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The company has disclosed positive interim data from Cohort 4 of their Phase 1b study, showing effective target engagement and a mechanistic dose response, which are encouraging signs for the drug’s potential efficacy.
Additionally, the alignment with the FDA on key components of a pivotal study for potential Accelerated Approval adds to the optimism. Despite the relatively small sample size in the Phase 1b study, the forthcoming topline data from all patients in Cohort 4 is anticipated to provide further confidence to investors. With plans to start a pivotal trial later this year and a Phase 3 study expected to begin in the third quarter of 2025, Regulus is strategically positioning itself for future growth. The company’s financial position, with $75.8 million in cash and investments, is expected to support its operations into early 2026, further supporting the Buy rating.
In another report released on March 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com